Inventor Search #2

Schnizer 09/627,787

L8 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2001 ACS
AN 2001:101001 HCAPLUS
DN 134:183461
TI **Conjugates** and methods for the production thereof for transporting molecules across biological **membranes**
IN **Uhlmann, Eugen; Greiner, Beate; Unger, Eberhard; Gothe, Gislinde; Schwerdel, Marc**
PA Aventis Pharma Deutschland Gmbh, Germany
SO PCT Int. Appl., 84 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001008707	A2	20010208	WO 2000-EP6936	20000720
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	DE 19935302	A1	20010208	DE 1999-19935302	19990728
PRAI	DE 1999-19935302	A	19990728		

OS MARPAT 134:183461
AB The invention relates to **conjugates**, methods for their prodn., and to the use of these **conjugates** for transporting low mol. wt. compds. and macromols. across biol. **membranes**, in particular, for transporting mols. into cells. The invention also relates to medicaments, diagnostic agents and test kits in which these **conjugates** are present or introduced.
IT **89962-57-2P 325760-02-9P 325760-03-0P 325760-04-1P 325760-05-2P 325760-06-3P 325760-07-4P 325760-08-5P 325760-09-6DP, conjugate** with Cy3 **325760-10-9P**
RL: BPR (Biological process); PEP (Physical, engineering or chemical process); PNU (Preparation, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(**conjugates** for transporting mols. across biol. **membranes**)
RN 89962-57-2 HCAPLUS
CN Adenosine, 2'-deoxyadenylyl-(3'.fwdarw.5')-2'-deoxyadenylyl-(3'.fwdarw.5')-2'-deoxyadenylyl-(3'.fwdarw.5')-2'-deoxyadenylyl-(3'.fwdarw.5')-2'-deoxyadenylyl-(3'.fwdarw.5')-2'-deoxyadenylyl-(3'.fwdarw.5')-2'-deoxyadenylyl-(3'.fwdarw.5')-2'-deoxyadenylyl-(3'.fwdarw.5')-2'-deoxyadenylyl-(3'.fwdarw.5')-2'-deoxyadenylyl-(3'.fwdarw.5')-2'-deoxy- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 325760-02-9 HCAPLUS
CN DNA, d(D-G-C-G-A-C-G-C-C-A-T-G-A-C-G-G) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 325760-03-0 HCAPLUS
CN DNA, d(D-C-G-A-C-G-C-C-A-T-G-A-C) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 325760-04-1 HCAPLUS
CN DNA, d(D-A-T-G-A-C-G-G-A-A-T-T-C) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 325760-05-2 HCAPLUS
CN DNA, d(D-T-A-T-T-C-C-G-T-C-A-T) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 325760-06-3 HCAPLUS
CN DNA, d(A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-
A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 325760-07-4 HCAPLUS
CN DNA, d(A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-
A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-
A-A-A-A-A-A-A-A-A) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 325760-08-5 HCAPLUS
CN DNA, d(T-T-C-C-A-T-G-G-T-G-G-C) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 325760-09-6 HCAPLUS
CN DNA, d(T-T-C-A-C-T-G-T-G-G-G-C) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 325760-10-9 HCAPLUS
CN DNA, d(T-G-G-C-G-C-C-G-G-G-C-C) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **146397-20-8D**, Cy3, **conjugate** with oligonucleotides
RL: BPR (Biological process); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(transport of; **conjugates** for transporting mols. across biol. **membranes**)
RN 146397-20-8 HCAPLUS
CN 3H-Indolium, 1-[6-[(2,5-dioxo-1-pyrrolidinyl)oxy]-6-oxohexyl]-2-[3-[1-[6-[(2,5-dioxo-1-pyrrolidinyl)oxy]-6-oxohexyl]-1,3-dihydro-3,3-dimethyl-5-sulfo-2H-indol-2-ylidene]-1-propenyl]-3,3-dimethyl-5-sulfo-, inner salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



IT **104053-06-7 110616-00-7 116364-61-5**
121938-12-3 121962-43-4 131593-63-0
146216-12-8 147655-52-5 147786-19-4
153426-37-0 155002-55-4 155002-57-6
161415-79-8 161415-81-2 163665-40-5
164910-61-6 165447-62-1 166436-80-2
173432-53-6 173432-56-9 173432-57-0
173432-58-1 173432-59-2 173432-60-5
173432-61-6 173432-62-7 173432-63-8
173432-67-2 173432-68-3 173432-69-4
173432-70-7 173432-71-8 188134-42-1
188704-72-5 246223-25-6 259082-59-2
259082-61-6 259082-72-9 259082-73-0
259082-74-1 259082-78-5 259082-79-6
259082-80-9 259082-81-0 259082-82-1
259082-83-2 259082-97-8 259083-00-6
259083-01-7 325761-26-0 325761-27-1
325761-28-2, 5: PN: WO0108707 SEQID: 23 unclaimed DNA
325761-29-3

RL: PRP (Properties)
(unclaimed nucleotide sequence; **conjugates** and methods for the prodn. thereof for transporting mols. across biol. **membranes**)
RN 104053-06-7 HCAPLUS
CN Guanosine, 2'-deoxyadenylyl-(3'.fwdarw.5')-2'-deoxycytidylyl-(3'.fwdarw.5')-2'-deoxyadenylyl-(3'.fwdarw.5')-2'-deoxycytidylyl-(3'.fwdarw.5')-2'-deoxycytidylyl-(3'.fwdarw.5')-2'-deoxyadenylyl-(3'.fwdarw.5')-2'-deoxyadenylyl-(3'.fwdarw.5')-thymidylyl-(3'.fwdarw.5')-thymidylyl-(3'.fwdarw.5')-2'-deoxycytidylyl-(3'.fwdarw.5')-thymidylyl-(3'.fwdarw.5')-2'-deoxyguanylyl-(3'.fwdarw.5')-2'-deoxyadenylyl-(3'.fwdarw.5')-2'-deoxyadenylyl-(3'.fwdarw.5')-2'-deoxyadenylyl-(3'.fwdarw.5')-thymidylyl-(3'.fwdarw.5')-2'-deoxyguanylyl-(3'.fwdarw.5')-2'-deoxy- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 110616-00-7 HCAPLUS
CN Adenosine, thymidylyl-(5'.fwdarw.3')-2'-deoxyadenylyl-(5'.fwdarw.3')-2'-deoxycytidylyl-(5'.fwdarw.3')-2'-deoxyguanylyl-(5'.fwdarw.3')-2'-deoxyguanylyl-(5'.fwdarw.3')-2'-deoxyguanylyl-(5'.fwdarw.3')-2'-deoxyadenylyl-(5'.fwdarw.3')-2'-deoxyguanylyl-(5'.fwdarw.3')-thymidylyl-(5'.fwdarw.3')-thymidylyl-(5'.fwdarw.3')-2'-deoxyguanylyl-(5'.fwdarw.3')-2'-deoxycytidylyl-(5'.fwdarw.3')-2'-deoxyadenylyl-(5'.fwdarw.3')-2'-deoxy- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 116364-61-5 HCAPLUS
CN DNA, d(T-A-T-T-C-C-G-T-C-A-T) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A



PAGE 2-A



PAGE 2-B



PAGE 3-A





PAGE 3-B



PAGE 4-A

RN 121938-12-3 HCAPLUS
CN Guanosine, 2'-deoxycytidylyl-(5'.fwdarw.3')-2'-deoxyguanylyl-(5'.fwdarw.3')-2'-deoxyguanylyl-(5'.fwdarw.3')-2'-deoxyguanylyl-(5'.fwdarw.3')-2'-deoxycytidylyl-(5'.fwdarw.3')-thymidylyl-(5'.fwdarw.3')-thymidylyl-(5'.fwdarw.3')-2'-deoxycytidylyl-(5'.fwdarw.3')-thymidylyl-(5'.fwdarw.3')-2'-deoxyguanylyl-(5'.fwdarw.3')-2'-deoxyguanylyl-(5'.fwdarw.3')-2'-deoxyguanylyl-(5'.fwdarw.3')-2'-deoxyguanylyl-(5'.fwdarw.3')-2'-deoxycytidylyl-(5'.fwdarw.3')-2'-deoxycytidylyl-(5'.fwdarw.3')-2'-deoxyguanylyl-(5'.fwdarw.3')-thymidylyl-(5'.fwdarw.3')-2'-deoxy- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 121962-43-4 HCAPLUS
CN Guanosine, 2'-deoxycytidylyl-(5'.fwdarw.3')-2'-deoxyguanylyl-(5'.fwdarw.3')-2'-deoxyguanylyl-(5'.fwdarw.3')-2'-deoxyguanylyl-(5'.fwdarw.3')-2'-deoxycytidylyl-(5'.fwdarw.3')-2'-deoxycytidylyl-(5'.fwdarw.3')-thymidylyl-(5'.fwdarw.3')-2'-deoxycytidylyl-(5'.fwdarw.3')-thymidylyl-(5'.fwdarw.3')-2'-deoxyguanylyl-(5'.fwdarw.3')-2'-deoxyguanylyl-(5'.fwdarw.3')-2'-deoxyguanylyl-(5'.fwdarw.3')-2'-deoxycytidylyl-(5'.fwdarw.3')-thymidylyl-(5'.fwdarw.3')-2'-deoxyguanylyl-(5'.fwdarw.3')-thymidylyl-(5'.fwdarw.3')-2'-deoxy- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 131593-63-0 HCAPLUS
CN DNA, d(G-G-C-T-G-C-T-G-G-A-G-C-G-G-G-G-C-A-C-A-C) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 146216-12-8 HCAPLUS
CN Guanosine, 2'-deoxycytidylyl-(5'.fwdarw.3')-2'-deoxyguanylyl-(5'.fwdarw.3')-2'-deoxyguanylyl-(5'.fwdarw.3')-thymidylyl-(5'.fwdarw.3')-2'-deoxycytidylyl-(5'.fwdarw.3')-2'-deoxyadenylyl-(5'.fwdarw.3')-2'-deoxycytidylyl-(5'.fwdarw.3')-thymidylyl-(5'.fwdarw.3')-2'-deoxycytidylyl-(5'.fwdarw.3')-2'-deoxycytidylyl-(5'.fwdarw.3')-thymidylyl-(5'.fwdarw.3')-2'-deoxycytidylyl-(5'.fwdarw.3')-2'-deoxycytidylyl-(5'.fwdarw.3')-2'-deoxyguanylyl-(5'.fwdarw.3')-thymidylyl-(5'.fwdarw.3')-2'-deoxyguanylyl-(5'.fwdarw.3')-2'-deoxycytidylyl-(5'.fwdarw.3')-2'-deoxy- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 147655-52-5 HCAPLUS
CN Thymidine, 2'-deoxycytidylyl-(3'.fwdarw.5')-2'-deoxyadenylyl-(3'.fwdarw.5')-2'-deoxycytidylyl-(3'.fwdarw.5')-2'-deoxyguanylyl-(3'.fwdarw.5')-thymidylyl-(3'.fwdarw.5')-thymidylyl-(3'.fwdarw.5')-2'-deoxyguanylyl-(3'.fwdarw.5')-2'-deoxyadenylyl-(3'.fwdarw.5')-2'-deoxyguanylyl-(3'.fwdarw.5')-2'-deoxyguanylyl-(3'.fwdarw.5')-2'-deoxyguanylyl-(3'.fwdarw.5')-2'-deoxycytidylyl-(3'.fwdarw.5')-2'-deoxyadenylyl-(3'.fwdarw.5')- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 147786-19-4 HCAPLUS
CN Guanosine, 2'-deoxyadenylyl-(5'.fwdarw.3')-2'-deoxyadenylyl-(5'.fwdarw.3')-2'-deoxyadenylyl-(5'.fwdarw.3')-2'-deoxycytidylyl-(5'.fwdarw.3')-thymidylyl-(5'.fwdarw.3')-2'-deoxycytidylyl-(5'.fwdarw.3')-2'-deoxycytidylyl-(5'.fwdarw.3')-2'-deoxyguanylyl-(5'.fwdarw.3')-thymidylyl-(5'.fwdarw.3')-2'-deoxyguanylyl-(5'.fwdarw.3')-2'-deoxycytidylyl-(5'.fwdarw.3')-2'-deoxyguanylyl-(5'.fwdarw.3')-2'-deoxyguanylyl-(5'.fwdarw.3')-2'-deoxyadenylyl-(5'.fwdarw.3')-2'-deoxycytidylyl-(5'.fwdarw.3')-thymidylyl-(5'.fwdarw.3')-2'-deoxyadenylyl-(5'.fwdarw.3')-2'-deoxy- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 153426-37-0 HCAPLUS
CN Thymidine, thymidylyl-(3'.fwdarw.5')-2'-deoxycytidylyl-(3'.fwdarw.5')-thymidylyl-(3'.fwdarw.5')-2'-deoxycytidylyl-(3'.fwdarw.5')-2'-deoxycytidylyl-(3'.fwdarw.5')-2'-deoxycytidylyl-(3'.fwdarw.5')-2'-deoxyadenylyl-(3'.fwdarw.5')-2'-deoxyguanylyl-(3'.fwdarw.5')-2'-deoxycytidylyl-(3'.fwdarw.5')-2'-deoxyguanylyl-(3'.fwdarw.5')-thymidylyl-(3'.fwdarw.5')-2'-deoxyguanylyl-(3'.fwdarw.5')-2'-deoxycytidylyl-(3'.fwdarw.5')-2'-deoxyguanylyl-(3'.fwdarw.5')-2'-deoxycytidylyl-(3'.fwdarw.5')-2'-deoxycytidylyl-(3'.fwdarw.5')-2'-deoxyadenylyl-(3'.fwdarw.5')- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 155002-55-4 HCAPLUS
CN DNA, d(C-C-C-C-C-A-C-C-A-C-T-T-C-C-C-C-T-C-T-C) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 155002-57-6 HCAPLUS

CN DNA, d(G-C-C-C-A-A-G-C-T-G-G-C-A-T-C-C-G-T-C-A) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 161415-79-8 HCAPLUS
CN DNA, d(G-G-C-T-G-C-C-A-T-G-G-T-C-C-C) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 161415-81-2 HCAPLUS
CN DNA, d(G-T-C-T-T-C-C-A-T-A-G-T-T-A-C-T-C-A) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 163665-40-5 HCAPLUS
CN DNA, d(G-T-T-C-T-C-G-C-T-G-G-T-G-A-G-T-T-T-C-A) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 164910-61-6 HCAPLUS
CN DNA, d(G-C-G-T-T-T-G-C-T-C-T-T-C-T-T-C-T-T-G-C-G) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 165447-62-1 HCAPLUS
CN DNA, d(G-C-G-G-G-G-C-T-C-C-A-T-G-G-G-G-T-C-G) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 166436-80-2 HCAPLUS
CN DNA, d(C-A-C-C-C-G-C-C-T-T-G-G-C-C-T-C-C-C-A-C) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 173432-53-6 HCAPLUS
CN DNA, d(A-G-G-T-C-C-C-T-G-T-T-C-G-G-G-C-G-C-C-A) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 173432-56-9 HCAPLUS
CN DNA, d(C-A-G-C-T-G-C-A-A-C-C-C-A-G-C) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 173432-57-0 HCAPLUS
CN DNA, d(G-G-A-G-A-A-C-A-T-C-A-T-G-G-T-C-G-A-A-A-G) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 173432-58-1 HCAPLUS
CN DNA, d(C-C-C-G-A-G-A-A-C-A-T-C-A-T-G-G-T-C-G-A-A-G) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 173432-59-2 HCAPLUS
CN DNA, d(G-G-G-G-A-A-A-G-C-C-C-G-G-C-A-A-G-G-G-G) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 173432-60-5 HCAPLUS
CN DNA, d(G-G-G-A-C-T-C-C-G-G-C-G-C-A-G-C-G-C) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 173432-61-6 HCAPLUS
CN DNA, d(G-G-C-A-A-A-C-T-T-T-C-T-T-T-T-C-C-T-C-C) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 173432-62-7 HCAPLUS
CN DNA, d(G-G-G-A-A-G-G-A-G-G-A-G-G-A-T-G-A-G-G) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 173432-63-8 HCAPLUS
CN DNA, d(G-G-C-A-G-T-C-A-T-C-C-A-G-C-T-T-C-G-G-A-G) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 173432-67-2 HCAPLUS
CN DNA, d(G-C-A-G-T-A-A-G-C-A-T-C-C-A-T-A-T-C) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 173432-68-3 HCAPLUS
CN DNA, d(C-T-C-C-C-C-C-A-C-C-A-C-T-T-C-C-C-C-T-C) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 173432-69-4 HCAPLUS
CN DNA, d(G-C-T-G-G-G-A-G-C-C-A-T-A-G-C-G-A-G-G) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 173432-70-7 HCAPLUS
CN DNA, d(A-C-T-G-C-T-G-C-C-T-C-T-T-G-T-C-T-C-A-G-G) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 173432-71-8 HCAPLUS
CN DNA, d(C-A-A-T-C-A-A-T-G-A-C-T-T-C-A-A-G-A-G-T-T-C) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 188134-42-1 HCAPLUS
CN DNA, d(T-C-C-C-G-C-C-T-G-T-G-A-C-A-T-G-C-A-T-T) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 188704-72-5 HCAPLUS
CN DNA, d(G-A-T-G-G-A-G-G-G-C-G-G-C-A-T-G-G-C-G-G-G) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 246223-25-6 HCAPLUS
CN DNA, d(G-C-G-G-C-G-G-A-A-A-A-G-C-C-A-T-C-G) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 259082-59-2 HCAPLUS
CN DNA, d(G-G-A-G-G-C-C-C-G-A-C-C) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 259082-61-6 HCAPLUS
CN DNA, d(G-G-T-T-T-C-G-G-A-G-G-C) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 259082-72-9 HCAPLUS
CN DNA, d(T-G-G-T-G-G-A-G-G-T-A-G) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 259082-73-0 HCAPLUS
CN DNA, d(G-C-A-T-G-G-T-G-G-A-G-G) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 259082-74-1 HCAPLUS
CN DNA, d(T-T-G-G-C-A-T-G-G-T-G-G) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 259082-78-5 HCAPLUS
CN DNA, d(G-C-C-T-G-G-G-A-C-C-A-C) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 259082-79-6 HCAPLUS
CN DNA, d(C-A-G-C-C-T-G-G-G-A-C-C) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 259082-80-9 HCAPLUS
CN DNA, d(T-G-C-A-G-C-C-T-G-G-G-A) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 259082-81-0 HCAPLUS
CN DNA, d(G-T-G-C-A-G-C-C-T-G-G-G) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 259082-82-1 HCAPLUS
CN DNA, d(G-G-T-G-C-A-G-C-C-T-G-G) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 259082-83-2 HCAPLUS
CN DNA, d(A-T-G-G-G-T-G-C-A-G-C-C) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 259082-97-8 HCAPLUS
CN DNA, d(G-G-C-T-T-G-A-A-G-A-T-G) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 259083-00-6 HCAPLUS
CN DNA, d(G-C-A-G-C-C-C-C-C-G-C-A) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 259083-01-7 HCAPLUS
CN DNA, d(G-C-A-G-C-A-G-C-C-C-C-C) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 325761-26-0 HCAPLUS
CN 11: PN: WO0108707 SEQID: 11 unclaimed DNA (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 325761-27-1 HCAPLUS
CN 18: PN: WO0108707 SEQID: 18 unclaimed DNA (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 325761-28-2 HCAPLUS
CN 5: PN: WO0108707 SEQID: 23 unclaimed DNA (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 325761-29-3 HCAPLUS
CN 15: PN: WO0108707 SEQID: 33 unclaimed DNA (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L8 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2001 ACS
AN 1999:220014 HCAPLUS
DN 130:249137

Schnizer 09/627,787

TI Novel targeted ultrasound imaging contrast agents for diagnostic and therapeutic use
IN **Unger, Evan C.**; Fritz, Thomas A.; Gertz, Edward W.
PA ImarRx Pharmaceutical Corp., USA
SO PCT Int. Appl., 223 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9913919	A1	19990325	WO 1998-US18858	19980909
	W: AU, CA				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 6139819	A	20001031	US 1997-932273	19970917
	AU 9893830	A1	19990405	AU 1998-93830	19980909
	EP 959908	A1	19991201	EP 1998-946919	19980909
	R: DE, FR, GB, IT				
PRAI	US 1997-932273	A	19970917		
	US 1995-497684	B2	19950607		
	US 1996-640464	B2	19960501		
	US 1996-660032	B2	19960606		
	US 1996-666129	A2	19960619		
	WO 1998-US18858	W	19980909		

AB This invention describes novel contrast agents which may be used for diagnostic and therapeutic use. The compns. may comprise a lipid, a protein, polymer and/or surfactant, and a gas, in combination with a targeting ligand. In preferred embodiments, the targeting ligand targets coagula, including emboli and/or thrombi, particularly in patients suffering from an arrhythmic disorder. The contrast media can be used in conjunction with diagnostic imaging, such as ultrasound, as well as therapeutic applications, such as therapeutic ultrasound.

IT **50-21-5D**, Lactic acid, polymer contg. **63-89-8**, Dipalmitoylphosphatidylcholine **75-21-8D**, Ethylene oxide, polymer contg. **75-56-9D**, Propylene oxide, polymer contg. **75-73-0** **76-16-4**, Perfluoroethane **76-19-7**, Perfluoropropane **79-06-1D**, Acrylamide, N-substituted derivs., polymer contg. **79-10-7D**, Acrylic acid, hydroxyalkyl derivs., polymer contg. **79-14-1D**, Glycolic acid, polymer contg. **79-41-4D**, Methacrylic acid, hydroxyalkyl derivs., polymer contg. **80-05-7D**, Bisphenol A, polymer contg. **80-62-6D**, Methyl methacrylate, polymer contg. **88-12-0D**, N-Vinyl-2-pyrrolidone, polymer contg. **100-42-5D**, Styrene, polymer contg. **106-89-8D**, polymer contg. **107-02-8D**, Acrolein, polymer contg. **107-13-1D**, Acrylonitrile, polymer contg. **107-21-1D**, Ethylene glycol, polymer contg. **108-05-4D**, Vinyl acetate, polymer contg. **115-25-3**, Perfluorocyclobutane **140-88-5D**, Ethyl acrylate, polymer contg. **151-56-4D**, Ethyleneimine, polymer contg. **307-34-6**, Perfluorooctane **335-57-9**, Perfluoroheptane **355-25-9**, Perfluorobutane **355-42-0**, Perfluorohexane **375-96-2**, Perfluorononane **502-44-3D**, .epsilon.-Caprolactone, polymer contg. **678-26-2**, Perfluoropentane **816-94-4**, Distearoylphosphatidylcholine **868-77-9D**, 2-Hydroxyethyl methacrylate, polymer contg. **1187-59-3D**, N-substituted derivs., polymer contg. **1337-81-1D**, Vinyl pyridine, polymer contg. **1520-21-4D**,

p-Amino-styrene, polymer contg. **2252-84-8**, Heptafluoropropane **2551-62-4**, Sulfur hexafluoride **3724-65-0D**, Crotonic acid, polymer contg. **4004-05-1**, Dioleoylphosphatidylethanolamine **4235-95-4 4949-20-6D**, 2,4-Pentadien-1-ol, polymer contg. **5681-36-7**, Dipalmitoylphosphatidylethanolamine **7659-36-1D**, Aminoethyl methacrylate, polymer contg. **7727-37-9**, Nitrogen, analysis **7782-41-4D**, Fluorine, gas contg. **9002-89-5**, Polyvinyl alcohol **9002-98-6 9003-01-4**, Polyacrylic acid **9003-05-8 9003-39-8**, Polyvinylpyrrolidone **9003-54-7 9011-14-7**, Polymethylmethacrylate **9016-00-6**, Polydimethylsiloxane **9016-00-6D**, Dimethylsiloxane, polymer contg. **15802-18-3D**, polymer contg. **18194-24-6**, Dimyristoylphosphatidylcholine **19698-29-4**, Dipalmitoylphosphatidic acid **24980-41-4**, Poly(.epsilon.-caprolactone) **25014-12-4**, Polymethacrylamide **25087-26-7**, Polymethacrylic acid **25248-42-4**, Poly[oxy(1-oxo-1,6-hexanediyl)] **25322-68-3 25322-69-4**, Poly(propylene oxide) **26023-30-3**, Poly[oxy(1-methyl-2-oxo-1,2-ethanediyl)] **26100-51-6**, Polylactic acid **26913-06-4**, Poly[imino(1,2-ethanediyl)] **27457-28-9D**, Sodium styrene sulfonate, polymer contg. **31900-57-9**, Polydimethylsiloxane **45103-52-4D**, polymer contg. **78543-25-6**, 1-Hexadecyl-2-palmitoylglycerophosphoethanolamine **97782-02-0 208345-02-2 208345-03-3 217098-79-8D**, polymer contg.
RL: ARU (Analytical role, unclassified); BUU (Biological use, unclassified); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(contrast agent; novel targeted ultrasound imaging contrast agents for diagnostic and therapeutic use)

RN 50-21-5 HCAPLUS
CN Propanoic acid, 2-hydroxy- (9CI) (CA INDEX NAME)



RN 63-89-8 HCAPLUS
CN 3,5,9-Trioxa-4-phosphapentacosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[(1-oxohexadecyl)oxy]-, inner salt, 4-oxide, (7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 75-21-8 HCAPLUS
CN Oxirane (9CI) (CA INDEX NAME)

RN 75-56-9 HCAPLUS
CN Oxirane, methyl- (9CI) (CA INDEX NAME)



RN 75-73-0 HCAPLUS
CN Methane, tetrafluoro- (9CI) (CA INDEX NAME)



RN 76-16-4 HCAPLUS
CN Ethane, hexafluoro- (8CI, 9CI) (CA INDEX NAME)

RN 76-19-7 HCAPLUS
CN Propane, octafluoro- (6CI, 8CI, 9CI) (CA INDEX NAME)

$F_3C-CF_2-CF_3$

RN 79-06-1 HCAPLUS
CN 2-Propenamide (9CI) (CA INDEX NAME)



RN 79-10-7 HCAPLUS
CN 2-Propenoic acid (9CI) (CA INDEX NAME)



RN 79-14-1 HCAPLUS
CN Acetic acid, hydroxy- (9CI) (CA INDEX NAME)



RN 79-41-4 HCAPLUS
CN 2-Propenoic acid, 2-methyl- (9CI) (CA INDEX NAME)



RN 80-05-7 HCAPLUS
CN Phenol, 4,4'-(1-methylethylidene)bis- (9CI) (CA INDEX NAME)



RN 80-62-6 HCAPLUS
CN 2-Propenoic acid, 2-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 88-12-0 HCAPLUS
CN 2-Pyrrolidinone, 1-ethenyl- (9CI) (CA INDEX NAME)



RN 100-42-5 HCAPLUS
CN Benzene, ethenyl- (9CI) (CA INDEX NAME)

$H_2C{=}CH{-}Ph$

RN 106-89-8 HCAPLUS
CN Oxirane, (chloromethyl)- (9CI) (CA INDEX NAME)



RN 107-02-8 HCAPLUS
CN 2-Propenal (9CI) (CA INDEX NAME)

$H_2C{=}CH{-}CH{=}O$

RN 107-13-1 HCAPLUS
CN 2-Propenenitrile (9CI) (CA INDEX NAME)

$H_2C{=}CH{-}C{\equiv}N$

RN 107-21-1 HCAPLUS
CN 1,2-Ethanediol (9CI) (CA INDEX NAME)

$HO{-}CH_2{-}CH_2{-}OH$

RN 108-05-4 HCAPLUS
CN Acetic acid ethenyl ester (9CI) (CA INDEX NAME)



RN 115-25-3 HCAPLUS
CN Cyclobutane, octafluoro- (6CI, 8CI, 9CI) (CA INDEX NAME)



RN 140-88-5 HCAPLUS
CN 2-Propenoic acid, ethyl ester (9CI) (CA INDEX NAME)



RN 151-56-4 HCAPLUS
CN Aziridine (9CI) (CA INDEX NAME)

RN 307-34-6 HCAPLUS
CN Octane, octadecafluoro- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 335-57-9 HCAPLUS
CN Heptane, hexadecafluoro- (6CI, 8CI, 9CI) (CA INDEX NAME)



RN 355-25-9 HCAPLUS
CN Butane, decafluoro- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)

$F_3C-CF_2-CF_2-CF_3$

RN 355-42-0 HCAPLUS
CN Hexane, tetradecafluoro- (6CI, 8CI, 9CI) (CA INDEX NAME)

$F_3C-(CF_2)_4-CF_3$

RN 375-96-2 HCAPLUS
CN Nonane, eicosafluoro- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)

$F_3C-(CF_2)_7-CF_3$

RN 502-44-3 HCAPLUS
CN 2-Oxepanone (8CI, 9CI) (CA INDEX NAME)



RN 678-26-2 HCAPLUS
CN Pentane, dodecafluoro- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)

$F_3C-(CF_2)_3-CF_3$

RN 816-94-4 HCAPLUS
CN 3,5,9-Trioxa-4-phosphaheptacosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[(1-oxooctadecyl)oxy]-, inner salt, 4-oxide, (7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 868-77-9 HCAPLUS
CN 2-Propenoic acid, 2-methyl-, 2-hydroxyethyl ester (9CI) (CA INDEX NAME)



RN 1187-59-3 HCAPLUS
CN 2-Propenamide, N-methyl- (9CI) (CA INDEX NAME)



RN 1337-81-1 HCAPLUS
CN Pyridine, ethenyl- (9CI) (CA INDEX NAME)





RN 1520-21-4 HCAPLUS
CN Benzenamine, 4-ethenyl- (9CI) (CA INDEX NAME)



RN 2252-84-8 HCAPLUS
CN Propane, 1,1,1,2,2,3,3-heptafluoro- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)

$F_2CH-CF_2-CF_3$

RN 2551-62-4 HCAPLUS
CN Sulfur fluoride (SF6), (OC-6-11)- (9CI) (CA INDEX NAME)



RN 3724-65-0 HCAPLUS
CN 2-Butenoic acid (9CI) (CA INDEX NAME)

$Me-CH=CH-CO_2H$

RN 4004-05-1 HCAPLUS
CN 9-Octadecenoic acid (9Z)-, (1R)-1-[[[(2-aminoethoxy)hydroxyphosphinyl]oxy]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

Me

RN 4235-95-4 HCAPLUS
CN 3,5,9-Trioxa-4-phosphaheptacos-18-en-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[[(9Z)-1-oxo-9-octadecenyl]oxy]-, inner salt, 4-oxide, (7R,18Z)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

Me

RN 4949-20-6 HCAPLUS
CN 2,4-Pentadien-1-ol (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 5681-36-7 HCAPLUS
CN Hexadecanoic acid, 1-[[[(2-aminoethoxy)hydroxyphosphinyl]oxy]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)



RN 7659-36-1 HCAPLUS
CN 2-Propenoic acid, 2-methyl-, 2-aminoethyl ester (9CI) (CA INDEX NAME)



RN 7727-37-9 HCAPLUS
CN Nitrogen (8CI, 9CI) (CA INDEX NAME)

RN 7782-41-4 HCAPLUS
CN Fluorine (8CI, 9CI) (CA INDEX NAME)



RN 9002-89-5 HCAPLUS
CN Ethenol, homopolymer (9CI) (CA INDEX NAME)

CM 1

CRN 557-75-5
CMF C2 H4 O

RN 9002-98-6 HCAPLUS
CN Aziridine, homopolymer (9CI) (CA INDEX NAME)

CM 1

CRN 151-56-4
CMF C2 H5 N

RN 9003-01-4 HCAPLUS
CN 2-Propenoic acid, homopolymer (9CI) (CA INDEX NAME)

CM 1

CRN 79-10-7
CMF C3 H4 O2



RN 9003-05-8 HCAPLUS
CN 2-Propenamide, homopolymer (9CI) (CA INDEX NAME)

CM 1

CRN 79-06-1
CMF C3 H5 N O



RN 9003-39-8 HCAPLUS
CN 2-Pyrrolidinone, 1-ethenyl-, homopolymer (9CI) (CA INDEX NAME)

CM 1

CRN 88-12-0
CMF C6 H9 N O



RN 9003-54-7 HCAPLUS
CN 2-Propenenitrile, polymer with ethenylbenzene (9CI) (CA INDEX NAME)

CM 1

CRN 107-13-1
CMF C3 H3 N



CM 2

CRN 100-42-5
CMF C8 H8

RN 9011-14-7 HCAPLUS
CN 2-Propenoic acid, 2-methyl-, methyl ester, homopolymer (9CI) (CA INDEX NAME)

CM 1

CRN 80-62-6
CMF C5 H8 O2



RN 9016-00-6 HCAPLUS
CN Poly[oxy(dimethylsilylene)] (8CI, 9CI) (CA INDEX NAME)



RN 9016-00-6 HCAPLUS
CN Poly[oxy(dimethylsilylene)] (8CI, 9CI) (CA INDEX NAME)



RN 15802-18-3 HCAPLUS
CN 2-Propenoic acid, 2-cyano- (9CI) (CA INDEX NAME)



RN 18194-24-6 HCAPLUS
CN 3,5,9-Trioxa-4-phosphatricosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[(1-oxotetradecyl)oxy]-, inner salt, 4-oxide, (7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 19698-29-4 HCAPLUS
CN Hexadecanoic acid, 1-[(phosphonooxy)methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)



RN 24980-41-4 HCAPLUS
CN 2-Oxepanone, homopolymer (9CI) (CA INDEX NAME)

CM 1

CRN 502-44-3
CMF C6 H10 O2



RN 25014-12-4 HCAPLUS
CN 2-Propenamide, 2-methyl-, homopolymer (9CI) (CA INDEX NAME)

CM 1

CRN 79-39-0
CMF C4 H7 N O



RN 25087-26-7 HCAPLUS
CN 2-Propenoic acid, 2-methyl-, homopolymer (9CI) (CA INDEX NAME)

CM 1

CRN 79-41-4
CMF C4 H6 O2



RN 25248-42-4 HCAPLUS
CN Poly[oxy(1-oxo-1,6-hexanediyl)] (9CI) (CA INDEX NAME)



RN 25322-68-3 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-hydro-.omega.-hydroxy- (9CI) (CA INDEX NAME)





RN 25322-69-4 HCAPLUS
CN Poly[oxy(methyl-1,2-ethanediyl)], .alpha.-hydro-.omega.-hydroxy- (9CI) (CA INDEX NAME)



RN 26023-30-3 HCAPLUS
CN Poly[oxy(1-methyl-2-oxo-1,2-ethanediyl)] (8CI, 9CI) (CA INDEX NAME)



RN 26100-51-6 HCAPLUS
CN Propanoic acid, 2-hydroxy-, homopolymer (9CI) (CA INDEX NAME)

CM 1

CRN 50-21-5
CMF C3 H6 O3



RN 26913-06-4 HCAPLUS
CN Poly[imino(1,2-ethanediyl)] (9CI) (CA INDEX NAME)



RN 27457-28-9 HCAPLUS
CN Benzenesulfonic acid, ethenyl-, sodium salt (9CI) (CA INDEX NAME)

D1— CH═ CH_2

D1— SO_3H

● Na

RN 31900-57-9 HCAPLUS
CN Silanediol, dimethyl-, homopolymer (9CI) (CA INDEX NAME)

CM 1

CRN 1066-42-8
CMF C2 H8 O2 Si



RN 45103-52-4 HCAPLUS
CN 2-Propenoic acid, 2-methyl-, 2-(sulfooxy)ethyl ester, sodium salt (9CI)
(CA INDEX NAME)



● Na

RN 78543-25-6 HCAPLUS
CN Hexadecanoic acid, 2-[[(2-aminoethoxy)hydroxyphosphinyl]oxy]-1-
[(hexadecyloxy)methyl]ethyl ester (9CI) (CA INDEX NAME)



RN 97782-02-0 HCAPLUS
CN 9-Octadecenoic acid (9Z)-, 1-[[[[2-(2,5-dioxo-1-pyrrolidinyl)ethoxy]hydroxyphosphinyl]oxy]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 208345-02-2 HCAPLUS
CN Ethenylidene, polymer with 2-propenenitrile (9CI) (CA INDEX NAME)

CM 1

CRN 2143-69-3
CMF C2 H2



CM 2

CRN 107-13-1
CMF C3 H3 N



RN 208345-03-3 HCAPLUS
CN Ethenylidene, polymer with methyl 2-methyl-2-propenoate and 2-propenenitrile (9CI) (CA INDEX NAME)

CM 1

CRN 2143-69-3
CMF C2 H2

CM 2

CRN 107-13-1
CMF C3 H3 N

CM 3

CRN 80-62-6
CMF C5 H8 O2



RN 217098-79-8 HCAPLUS
CN Benzenamine, 4-[(4-ethenylphenyl)methyl]- (9CI) (CA INDEX NAME)



IT **12629-01-5**, Human growth hormone
RL: ARU (Analytical role, unclassified); BPR (Biological process); BUU (Biological use, unclassified); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PROC (Process); USES (Uses)
(novel targeted ultrasound imaging contrast agents for diagnostic and therapeutic use)
RN 12629-01-5 HCAPLUS
CN Somatotropin (human) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **79481-27-9P 186750-22-1DP**, reaction products with protein A **221553-32-8P**
RL: ARU (Analytical role, unclassified); BUU (Biological use,

unclassified); SPN (Synthetic preparation); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
(novel targeted ultrasound imaging contrast agents for diagnostic and therapeutic use)

RN 79481-27-9 HCAPLUS

CN 3,5,8,21-Tetraoxa-4-phosphatetracos-23-en-1-aminium, 4-hydroxy-N,N,N,23-tetramethyl-9,22-dioxo-7-[[(1-oxohexadecyl)oxy]methyl]-, inner salt, 4-oxide, (7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186750-22-1 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), .alpha.-(carboxymethyl)-.omega.-[[(10R)-7-hydroxy-7-oxido-2,13-dioxo-10-[(1-oxohexadecyl)oxy]-6,8,12-trioxa-3-aza-7-phosphaoctacos-1-yl]oxy]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 221553-32-8 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), .alpha.-[(10R)-27,27,28,28,29,29,30,30,30-nonafluoro-7-hydroxy-10-[(15,15,16,16,17,17,18,18,18-nonafluoro-1-oxooctadecyl)oxy]-7-oxido-13-oxo-6,8,12-trioxa-3-aza-7-phosphatritriacont-1-yl]-.omega.-hydroxy-, 1-ether with N2-(2-hydroxyethyl)-L-arginylglycyl-L-.alpha.-aspartyl-L-serine (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 1-C

— $(CH_2)_{13}$— $(CF_2)_3$— CF_3

IT **9005-64-5**, Tween 20 **129849-35-0 221553-14-6**
221553-21-5D, reaction products with polyphosphazene
221553-36-2
RL: ARU (Analytical role, unclassified); BUU (Biological use, unclassified); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(novel targeted ultrasound imaging contrast agents for diagnostic and therapeutic use)

RN 9005-64-5 HCAPLUS

CN Sorbitan, monododecanoate, poly(oxy-1,2-ethanediyl) derivs. (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 129849-35-0 HCAPLUS
CN Poly[nitrilo[bis(4-carboxyphenoxy)phosphoranylidyne]] (9CI) (CA INDEX NAME)



RN 221553-14-6 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-[(10R)-7-hydroxy-7-oxido-2,13-dioxo-10-[(1-oxohexadecyl)oxy]-6,8,12-trioxa-3-aza-7-phosphaoctacos-1-yl]-.omega.-hydroxy- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 221553-21-5 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-hydro-.omega.-hydroxy-, monoether with N2-(2-hydroxyethyl)-L-lysyl-L-glutaminyl-L-alanylglycyl-L-.alpha.-aspartyl-L-valine (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

PAGE 1-B



RN 221553-36-2 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-(2-aminoethyl)-.omega.-[[(10R)-7-hydroxy-7-oxido-13-oxo-10-[(1-oxooctadecyl)oxy]-6,8,12-trioxa-3-aza-7-phosphatriacont-1-yl]oxy]- (9CI) (CA INDEX NAME)

PAGE 1-A

Me—





IT **9001-84-7**, Phospholipase A2
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BUU (Biological use, unclassified); BIOL (Biological study); PROC (Process); USES (Uses)
(novel targeted ultrasound imaging contrast agents for diagnostic and therapeutic use)
RN 9001-84-7 HCAPLUS
CN Phospholipase A2 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **106096-93-9**, Basic fibroblast growth factor
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(novel targeted ultrasound imaging contrast agents for diagnostic and therapeutic use)
RN 106096-93-9 HCAPLUS
CN Fibroblast growth factor, basic (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **127464-60-2**, Vascular endothelial growth factor
RL: BPR (Biological process); BSU (Biological study, unclassified); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(novel targeted ultrasound imaging contrast agents for diagnostic and therapeutic use)
RN 127464-60-2 HCAPLUS
CN Vascular endothelial growth factor (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **4537-78-4**, Distearoylphosphatidylglycerol **9005-49-6**, Heparin, biological studies **9012-76-4D**, Chitosan, basic fibroblast growth hormone **conjugate 18883-66-4**, Streptozocin **51110-01-1**, Somatostatin
RL: BPR (Biological process); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(novel targeted ultrasound imaging contrast agents for diagnostic and therapeutic use)
RN 4537-78-4 HCAPLUS
CN Octadecanoic acid, 1-[[[(2,3-dihydroxypropoxy)hydroxyphosphinyl]oxy]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)



RN 9005-49-6 HCAPLUS
CN Heparin (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 9012-76-4 HCAPLUS
CN Chitosan (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 18883-66-4 HCAPLUS
CN D-Glucose, 2-deoxy-2-[[(methylnitrosoamino)carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 51110-01-1 HCAPLUS
CN Somatostatin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **7440-70-2**, Calcium, biological studies **106392-12-5**, Pluronic F 68 **221553-50-0**
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(novel targeted ultrasound imaging contrast agents for diagnostic and therapeutic use)
RN 7440-70-2 HCAPLUS
CN Calcium (8CI, 9CI) (CA INDEX NAME)

Ca

RN 106392-12-5 HCAPLUS
CN Oxirane, methyl-, polymer with oxirane, block (9CI) (CA INDEX NAME)

CM 1

CRN 75-56-9
CMF C3 H6 O



CM 2

CRN 75-21-8
CMF C2 H4 O

RN 221553-50-0 HCAPLUS
CN 2-Propenoic acid, 3-cyano-2-methyl-, methyl ester, polymer with 2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethyl 2-methyl-2-propenoate (9CI) (CA INDEX NAME)

CM 1

CRN 221553-49-7
CMF C12 H23 N O5



CM 2

CRN 66396-68-7
CMF C6 H7 N O2



IT **24991-23-9 25513-46-6**, Polyglutamic acid
RL: BUU (Biological use, unclassified); RCT (Reactant); BIOL (Biological

study); USES (Uses)
(novel targeted ultrasound imaging contrast agents for diagnostic and therapeutic use)
RN 24991-23-9 HCAPLUS
CN Poly[imino[(1S)-1-(2-carboxyethyl)-2-oxo-1,2-ethanediyl]] (9CI) (CA INDEX NAME)



RN 25513-46-6 HCAPLUS
CN L-Glutamic acid, homopolymer (9CI) (CA INDEX NAME)

CM 1

CRN 56-86-0
CMF C5 H9 N O4
CDES 5:L

Absolute stereochemistry.



IT **221553-52-2P**
RL: BUU (Biological use, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(novel targeted ultrasound imaging contrast agents for diagnostic and therapeutic use)
RN 221553-52-2 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-[2-[[4-[(2R)-2,3-bis[(1-oxohexadecyl)oxy]propoxy]-1,4-dioxobutyl]amino]ethyl]-.omega.-hydroxy-, ether with cyclo[L-arginylglycyl-N-(2-hydroxyethyl)-L-asparaginyl-3-(aminomethyl)benzoyl-(2R)-2-(methylamino)butanoyl] (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 1-C

— $(CH_2)_{14}$ — Me

IT **221553-37-3P**
RL: BUU (Biological use, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(novel targeted ultrasound imaging contrast agents for diagnostic and therapeutic use)

RN 221553-37-3 HCAPLUS

CN 8,10,14-Trioxa-5-aza-9-phosphatriacontanoic acid, 9-hydroxy-4,15-dioxo-12-[(1-oxohexadecyl)oxy]-, 2-[[6-[bis(2-hydroxyethyl)amino]-4,8-di-1-piperidinylpyrimido[5,4-d]pyrimidin-2-yl](2-hydroxyethyl)amino]ethyl ester, 9-oxide, (12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



IT **57-88-5,** Cholest-5-en-3-ol (3.beta.)-, biological studies
58-32-2, Dipyridamole **81-81-2,** Warfarin
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(novel targeted ultrasound imaging contrast agents for diagnostic and therapeutic use)
RN 57-88-5 HCAPLUS
CN Cholest-5-en-3-ol (3.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 58-32-2 HCAPLUS
CN Ethanol, 2,2',2'',2'''-[(4,8-di-1-piperidinylpyrimido[5,4-d]pyrimidine-2,6-diyl)dinitrilo]tetrakis- (9CI) (CA INDEX NAME)



RN 81-81-2 HCAPLUS
CN 2H-1-Benzopyran-2-one, 4-hydroxy-3-(3-oxo-1-phenylbutyl)- (9CI) (CA INDEX NAME)



IT **74-88-4**, Iodomethane, reactions **110-70-3**, N,N'-Dimethylethylenediamine **143-27-1**, Hexadecylamine **407-25-0**, Trifluoroacetic acid anhydride **505-95-3**, 12-Hydroxy dodecanoic acid **598-21-0**, .alpha.-Bromoacetyl bromide **623-65-4**, Palmitoyl anhydride **920-46-7**, Methacryloyl chloride **1069-79-0 4196-35-4 5505-63-5**, D-Mannosamine hydrochloride **6066-82-6**, N-Hydroxysuccinimide **23911-25-3**, Ethylenediaminetetraacetic acid dianhydride

24424-99-5 24991-53-5 28319-77-9,
L-.alpha.-Glycerophosphocholine **32130-27-1 36653-82-4,**
Hexadecyl alcohol **39927-08-7 68181-17-9**
80755-87-9 91037-65-9 108032-13-9
139729-28-5 150525-42-1 186750-27-6
221553-26-0 221553-39-5 221553-42-0
221553-51-1
RL: RCT (Reactant)
(novel targeted ultrasound imaging contrast agents for diagnostic and therapeutic use)

RN 74-88-4 HCAPLUS
CN Methane, iodo- (8CI, 9CI) (CA INDEX NAME)

H_3C-I

RN 110-70-3 HCAPLUS
CN 1,2-Ethanediamine, N,N'-dimethyl- (9CI) (CA INDEX NAME)

$MeNH-CH_2-CH_2-NHMe$

RN 143-27-1 HCAPLUS
CN 1-Hexadecanamine (9CI) (CA INDEX NAME)

$H_2N-(CH_2)_{15}-Me$

RN 407-25-0 HCAPLUS
CN Acetic acid, trifluoro-, anhydride (6CI, 8CI, 9CI) (CA INDEX NAME)



RN 505-95-3 HCAPLUS
CN Dodecanoic acid, 12-hydroxy- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)

$HO_2C-(CH_2)_{11}-OH$

RN 598-21-0 HCAPLUS
CN Acetyl bromide, bromo- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 623-65-4 HCAPLUS
CN Hexadecanoic acid, anhydride (9CI) (CA INDEX NAME)



RN 920-46-7 HCAPLUS
CN 2-Propenoyl chloride, 2-methyl- (9CI) (CA INDEX NAME)



RN 1069-79-0 HCAPLUS
CN Octadecanoic acid, (1R)-1-[[[(2-aminoethoxy)hydroxyphosphinyl]oxy]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 4196-35-4 HCAPLUS
CN .alpha.-D-Glucopyranosyl bromide, 2,3,4,6-tetrakis-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 5505-63-5 HCAPLUS
CN D-Mannose, 2-amino-2-deoxy-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 6066-82-6 HCAPLUS
CN 2,5-Pyrrolidinedione, 1-hydroxy- (9CI) (CA INDEX NAME)



RN 23911-25-3 HCAPLUS
CN 2,6-Morpholinedione, 4,4'-(1,2-ethanediyl)bis- (9CI) (CA INDEX NAME)



RN 24424-99-5 HCAPLUS
CN Dicarbonic acid, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 24991-53-5 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-(2-aminoethyl)-.omega.-(2-aminoethoxy)-
(9CI) (CA INDEX NAME)



RN 28319-77-9 HCAPLUS
CN Ethanaminium, 2-[[[(2R)-2,3-dihydroxypropoxy]hydroxyphosphinyl]oxy]-N,N,N-
trimethyl-, inner salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 32130-27-1 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-(2-aminoethyl)-.omega.-hydroxy- (9CI)
(CA INDEX NAME)



RN 36653-82-4 HCAPLUS
CN 1-Hexadecanol (9CI) (CA INDEX NAME)



RN 39927-08-7 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-(carboxymethyl)-.omega.-(carboxymethoxy)- (9CI) (CA INDEX NAME)



RN 68181-17-9 HCAPLUS
CN 2,5-Pyrrolidinedione, 1-[1-oxo-3-(2-pyridinyldithio)propoxy]- (9CI) (CA INDEX NAME)



RN 80755-87-9 HCAPLUS
CN L-Valine, L-lysyl-L-glutaminyl-L-alanylglycyl-L-.alpha.-aspartyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 91037-65-9 HCAPLUS
CN L-Serine, L-arginylglycyl-L-.alpha.-aspartyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 108032-13-9 HCAPLUS
CN Butanedioic acid, mono[(2R)-2,3-bis[(1-oxohexadecyl)oxy]propyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 139729-28-5 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-(2-aminoethyl)-.omega.-(carboxymethoxy)- (9CI) (CA INDEX NAME)



RN 150525-42-1 HCAPLUS
CN 8,10,14-Trioxa-5-aza-9-phosphatriacontanoic acid, 9-hydroxy-4,15-dioxo-12-[(1-oxohexadecyl)oxy]-, 9-oxide, (12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186750-27-6 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-(2-aminoethyl)-.omega.-[[(15R)-12-hydroxy-12-oxido-4,7,8-trioxo-15-[(1-oxohexadecyl)oxy]-11,13,17-trioxa-3,8-diaza-12-phosphatritriacont-1-yl]oxy]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 221553-26-0 HCAPLUS
CN Octadecanoic acid, 15,15,16,16,17,17,18,18,18-nonafluoro-, 1-[[[(2-aminoethoxy)hydroxyphosphinyl]oxy]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)



RN 221553-39-5 HCAPLUS
CN 2-Butenoic acid, 4-[[3-[(2,5-dioxo-1-pyrrolidinyl)oxy]-3-oxopropyl]amino]-4-oxo- (9CI) (CA INDEX NAME)



RN 221553-42-0 HCAPLUS
CN 1H-Pyrrole-2,5-dione, 1-[3-[(2,5-dioxo-1-pyrrolidinyl)oxy]-3-oxopropoxy]- (9CI) (CA INDEX NAME)



RN 221553-51-1 HCAPLUS
CN Cyclo[L-arginylglycyl-L-.alpha.-aspartyl-3-(aminomethyl)benzoyl-(2R)-2-(methylamino)butanoyl] (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **56309-86-5P 78103-30-7P 79487-02-8P**
79605-84-8P 139729-27-4P 186750-12-9P
186750-13-0P 186750-15-2P 186750-18-5P
186750-19-6P 186750-20-9P 186750-22-1P
186750-23-2P 186750-25-4P 186750-28-7P
186750-29-8P 186750-33-4P 221553-04-4P
221553-29-3P 221553-45-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(novel targeted ultrasound imaging contrast agents for diagnostic and therapeutic use)

RN 56309-86-5 HCAPLUS

CN Glycine, N,N'-1,2-ethanediylbis[N-(carboxymethyl)-, 1,1'-dihexadecyl ester (9CI) (CA INDEX NAME)



RN 78103-30-7 HCAPLUS

CN D-Mannose, 2-[(bromoacetyl)amino]-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 79487-02-8 HCAPLUS
CN Dodecanoic acid, 12-[(2-methyl-1-oxo-2-propenyl)oxy]-, anhydride (9CI) (CA INDEX NAME)



RN 79605-84-8 HCAPLUS
CN 3,5,9,22-Tetraoxa-4-phosphapentacos-24-en-1-aminium, 4-hydroxy-N,N,N,24-tetramethyl-7-[[12-[(2-methyl-1-oxo-2-propenyl)oxy]-1-oxododecyl]oxy]-10,23-dioxo-, inner salt, 4-oxide, (7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 139729-27-4 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-(carboxymethyl)-.omega.-[2-[[(1,1-dimethylethoxy)carbonyl]amino]ethoxy]- (9CI) (CA INDEX NAME)



RN 186750-12-9 HCAPLUS
CN Glycine, N,N'-1,2-ethanediylbis[N-[2-(hexadecylamino)-2-oxoethyl]- (9CI) (CA INDEX NAME)



RN 186750-13-0 HCAPLUS
CN 2,5,8,11-Tetraazatridecan-13-amide, 11-[2-[[2-(dimethylamino)ethyl]amino]-2-oxoethyl]-N-hexadecyl-8-[2-(hexadecylamino)-2-oxoethyl]-2-methyl-6-oxo-(9CI) (CA INDEX NAME)



RN 186750-15-2 HCAPLUS
CN 2,5,8,11-Tetraazatridecan-13-oic acid, 11-(carboxymethyl)-8-[2-(hexadecyloxy)-2-oxoethyl]-2-methyl-6-oxo-, 13-hexadecyl ester (9CI) (CA INDEX NAME)



RN 186750-18-5 HCAPLUS
CN Hexadecanoic acid, (1R)-1-[[4-[(2,5-dioxo-1-pyrrolidinyl)oxy]-1,4-dioxobutoxy]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186750-19-6 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-[2-[[4-[(2R)-2,3-bis[(1-oxohexadecyl)oxy]propoxy]-1,4-dioxobutyl]amino]ethyl]-.omega.-(carboxymethoxy)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 186750-20-9 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-[2-[[4-[(2R)-2,3-bis[(1-oxohexadecyl)oxy]propoxy]-1,4-dioxobutyl]amino]ethyl]-.omega.-[2-[(2,5-dioxo-1-pyrrolidinyl)oxy]-2-oxoethoxy]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 186750-22-1 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-(carboxymethyl)-.omega.-[[(10R)-7-hydroxy-7-oxido-2,13-dioxo-10-[(1-oxohexadecyl)oxy]-6,8,12-trioxa-3-aza-7-phosphaoctacos-1-yl]oxy]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 186750-23-2 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-[2-[(2,5-dioxo-1-pyrrolidinyl)oxy]-2-oxoethyl]-.omega.-[[(10R)-7-hydroxy-7-oxido-2,13-dioxo-10-[(1-oxohexadecyl)oxy]-6,8,12-trioxa-3-aza-7-phosphaoctacos-1-yl]oxy]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 186750-25-4 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-(2-aminoethyl)-.omega.-[2-[[4-[(2R)-2,3-bis[(1-oxohexadecyl)oxy]propoxy]-1,4-dioxobutyl]amino]ethoxy]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 186750-28-7 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-[2-[[4-[(2R)-2,3-bis[(1-oxohexadecyl)oxy]propoxy]-1,4-dioxobutyl]amino]ethyl]-.omega.-[2-[[1-oxo-3-(2-pyridinyldithio)propyl]amino]ethoxy]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 186750-29-8 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-[12-hydroxy-12-oxido-4,7,18-trioxo-(15R)-15-[(1-oxohexadecyl)oxy]-11,13,17-trioxa-3,8-diaza-12-phosphatritriacont-1-yl]-.omega.-[2-[[1-oxo-3-(2-pyridinyldithio)propyl]amino]ethoxy]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 186750-33-4 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-[2-[(trifluoroacetyl)amino]ethyl]-.omega.-hydroxy- (9CI) (CA INDEX NAME)



RN 221553-04-4 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-(carboxymethyl)-.omega.-(carboxymethoxy)-, homopolymer (9CI) (CA INDEX NAME)

CM 1

CRN 39927-08-7
CMF (C2 H4 O)n C4 H6 O5
CCI PMS



RN 221553-29-3 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-(2-aminoethyl)-.omega.-[[(10R)-27,27,28,28,29,29,30,30,30-nonafluoro-7-hydroxy-10-[(15,15,16,16,17,17,18,18,18-nonafluoro-1-oxooctadecyl)oxy]-7-oxido-13-oxo-6,8,12-trioxa-3-aza-7-phosphatriacont-1-yl]oxy]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 221553-45-3 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-(2-aminoethyl)-.omega.-[2-(.alpha.-D-glucopyranosyloxy)ethoxy]- (9CI) (CA INDEX NAME)



IT **80294-15-1P 186750-11-8P 186750-14-1P**
186750-21-0P 186750-24-3P 186750-26-5P
186750-29-8DP, conjugate with protein A
221552-96-1P 221552-99-4P 221553-14-6DP, conj.
with protein A **221553-44-2DP, conjugate** with protein A
221553-46-4P 221553-48-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(novel targeted ultrasound imaging contrast agents for diagnostic and therapeutic use)

RN 80294-15-1 HCAPLUS
CN 3,5,9,22-Tetraoxa-4-phosphapentacos-24-en-1-aminium, 4-hydroxy-N,N,N,24-tetramethyl-10,23-dioxo-7-[(1-oxohexadecyl)oxy]-, inner salt, 4-oxide, (7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186750-11-8 HCAPLUS
CN 3,12-Diaza-6,9-diazoniatetradecane-1,14-diaminium, 6,9-bis[2-(hexadecylamino)-2-oxoethyl]-N,N,N,N',N',N',6,9-octamethyl-4,11-dioxo-, tetraiodide (9CI) (CA INDEX NAME)



●4 I^-

RN 186750-14-1 HCAPLUS
CN 12-Oxa-3,9-diaza-6-azoniaoctacosan-1-aminium, 9-(carboxymethyl)-6-[2-(hexadecyloxy)-2-oxoethyl]-N,N,N,6-tetramethyl-4,11-dioxo-, diiodide (9CI) (CA INDEX NAME)



●2 I^-

RN 186750-21-0 HCAPLUS
CN L-Valine, hydroxyacetyl-L-lysyl-L-glutaminyl-L-alanylglycyl-L-.alpha.-aspartyl-, monoether with .alpha.-[(10R)-7-hydroxy-7-oxido-2,13-dioxo-10-[(1-oxohexadecyl)oxy]-6,8,12-trioxa-3-aza-7-phosphaoctacos-1-yl]-.omega.-hydroxypoly(oxy-1,2-ethanediyl) (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 186750-24-3 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-[2-[[4-[(2R)-2,3-bis[(1-oxohexadecyl)oxy]propoxy]-1,4-dioxobutyl]amino]ethyl]-.omega.-[2-[[3-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxopropyl]amino]ethoxy]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 186750-26-5 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-[2-[[3-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxopropyl]amino]ethyl]-.omega.-[[(15R)-12-hydroxy-12-oxido-4,7,18-trioxo-15-[(1-oxohexadecyl)oxy]-11,13,17-trioxa-3,8-diaza-12-phosphatritriacont-1-yl]oxy]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 1-C

— $(CH_2)_{14}$ — Me

RN 186750-29-8 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-[12-hydroxy-12-oxido-4,7,18-trioxo-(15R)-15-[(1-oxohexadecyl)oxy]-11,13,17-trioxa-3,8-diaza-12-phosphatritriacont-1-yl]-.omega.-[2-[[1-oxo-3-(2-pyridinyldithio)propyl]amino]ethoxy]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 221552-96-1 HCAPLUS
CN 1,2-Ethanediaminium, N,N'-bis[2-[[2-(dimethylamino)ethyl]amino]-2-oxoethyl]-N,N'-[2-(hexadecylamino)-2-oxoethyl]-N,N'-dimethyl-, diiodide (9CI) (CA INDEX NAME)



RN 221552-99-4 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-[2-[[4-[(2R)-2,3-bis[(1-oxohexadecyl)oxy]propoxy]-1,4-dioxobutyl]amino]ethyl]-.omega.-hydroxy-, ether with N2-(2-hydroxyethyl)-L-lysyl-L-glutaminyl-L-alanylglycyl-L-.alpha.-aspartyl-L-valine (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 221553-14-6 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-[(10R)-7-hydroxy-7-oxido-2,13-dioxo-10-[(1-oxohexadecyl)oxy]-6,8,12-trioxa-3-aza-7-phosphaoctacos-1-yl]-.omega.-hydroxy- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 221553-44-2 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-[2-[[4-[(2R)-2,3-bis[(1-oxohexadecyl)oxy]propoxy]-1,4-dioxobutyl]amino]ethyl]-.omega.-[2-[[3-[(2,5-dioxo-3-pyrrolidinyl)thio]-1-oxopropyl]amino]ethoxy]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 221553-46-4 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), .alpha.-[2-[[4-[(2R)-2,3-bis[(1-oxohexadecyl)oxy]propoxy]-1,4-dioxobutyl]amino]ethyl]-.omega.-[2-(.alpha.-D-glucopyranosyloxy)ethoxy]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 221553-48-6 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), .alpha.-[2-[[4-[(2R)-2,3-bis[(1-oxohexadecyl)oxy]propoxy]-1,4-dioxobutyl]amino]ethyl]-.omega.-hydroxy-, 2-ether with 2-deoxy-2-[[[(2-hydroxyethyl)amino]acetyl]amino]-.alpha.-D-mannopyranose (9CI) (CA INDEX NAME)

PAGE 1-A







RE.CNT 4
RE
(1) Grinstaff; US 5505932 A 1996
(2) Lohrmann; US 5536489 A 1996
(3) Schneider, E; US 5380519 A 1995 HCAPLUS
(4) Schutt; US 5540909 A 1996

L8 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2001 ACS
AN 1999:133201 HCAPLUS
DN 130:165174
TI Methods of computed tomography using perfluorocarbon gaseous filled microspheres as contrast agents
IN **Unger, Evan C.**
PA ImaRx Pharmaceutical Corp., USA
SO U.S., 27 pp., Cont.-in-part of U.S. Ser. No. 247,656, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5874062	A	19990223	US 1995-445299	19950519
	US 5205290	A	19930427	US 1991-680984	19910405
	EP 804932	A2	19971105	EP 1997-201854	19920318
	EP 804932	A3	19981216		
	EP 804932	B1	20010516		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC

EP	1064953	A2	20010103	EP 2000-203214	19920318
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC				
US	5281408	A	19940125	US 1993-980594	19930119
US	5456900	A	19951010	US 1993-116982	19930907
WO	9532006	A1	19951130	WO 1995-US6499	19950522
	W: AU, CA, CN, JP				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU	9526013	A1	19951218	AU 1995-26013	19950522
AU	700799	B2	19990114		
EP	760684	A1	19970312	EP 1995-920616	19950522
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CN	1160357	A	19970924	CN 1995-193160	19950522
JP	10500692	T2	19980120	JP 1995-530494	19950522
US	5547656	A	19960820	US 1995-449090	19950524
US	5547656	B1	19990720	US 1995-449009	19950524
US	5527521	A	19960618	US 1995-456738	19950601
US	5527521	B1	19991109		
US	6117414	A	20000912	US 1997-968776	19971110
AU	9884206	A1	19981224	AU 1998-84206	19980911
AU	9914280	A1	19990527	AU 1999-14280	19990129
PRAI	US 1991-680984	A3	19910405		
	US 1993-980594	A3	19930119		
	US 1993-116982	A2	19930907		
	US 1994-247656	B2	19940523		
	EP 1992-910021	A3	19920318		
	EP 1997-201854	A3	19920318		
	US 1995-445299	A	19950519		
	WO 1995-US6499	W	19950522		
	US 1995-449090	A3	19950524		
	AU 1995-33103	A3	19951006		

AB The present invention is directed to a contrast medium useful for computed tomog. imaging, said contrast medium comprising stabilized gas and gaseous precursor filled microspheres, wherein the gas may be, for example, air or nitrogen, but may also be derived from a gaseous precursor, for example, perfluoropentane, and the microspheres are stabilized by being formed from a stabilizing compd., for example, a biocompatible lipid or polymer. In certain preferred embodiments, the biocompatible lipid comprises a phospholipid which is in the form of a lipid bilayer. A unique aspect of the present invention involves the use of perfluorocarbon gases which are capable of maintaining the integrity, and thus, enhancing the stability, of the microspheres.

IT **75-73-0**, Perfluoromethane **76-16-4**, Perfluoroethane
76-19-7, Perfluoropropane **115-25-3**, Perfluorocyclobutane
335-57-9, Perfluoroheptane **355-25-9**, Perfluorobutane
355-42-0, Perfluorohexane **678-26-2**, Perfluoropentane
RL: ARG (Analytical reagent use); BUU (Biological use, unclassified); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(contrast agent; methods of computed tomog. using perfluorocarbon gaseous filled lipid microspheres as contrast agents)

RN 75-73-0 HCAPLUS
CN Methane, tetrafluoro- (9CI) (CA INDEX NAME)



RN 76-16-4 HCAPLUS
CN Ethane, hexafluoro- (8CI, 9CI) (CA INDEX NAME)



RN 76-19-7 HCAPLUS
CN Propane, octafluoro- (6CI, 8CI, 9CI) (CA INDEX NAME)

$F_3C-CF_2-CF_3$

RN 115-25-3 HCAPLUS
CN Cyclobutane, octafluoro- (6CI, 8CI, 9CI) (CA INDEX NAME)



RN 335-57-9 HCAPLUS
CN Heptane, hexadecafluoro- (6CI, 8CI, 9CI) (CA INDEX NAME)

$F_3C-(CF_2)_5-CF_3$

RN 355-25-9 HCAPLUS
CN Butane, decafluoro- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)

$F_3C-CF_2-CF_2-CF_3$

RN 355-42-0 HCAPLUS
CN Hexane, tetradecafluoro- (6CI, 8CI, 9CI) (CA INDEX NAME)



RN 678-26-2 HCAPLUS
CN Pentane, dodecafluoro- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



IT **5681-36-7D**, Dipalmitoylphosphatidylethanolamine, polyethylene glycol 5000 **conjugate 25322-68-3D**, dipalmitoylphosphatidylethanolamine **conjugate**
RL: ARG (Analytical reagent use); BUU (Biological use, unclassified); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(methods of computed tomog. using perfluorocarbon gaseous filled lipid microspheres as contrast agents)

RN 5681-36-7 HCAPLUS
CN Hexadecanoic acid, 1-[[[(2-aminoethoxy)hydroxyphosphinyl]oxy]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

RN 25322-68-3 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-hydro-.omega.-hydroxy- (9CI) (CA INDEX NAME)



IT **63-89-8 5681-36-7**, Dipalmitoylphosphatidylethanolamine **7727-37-9**, Nitrogen, biological studies **9002-89-5**, Polyvinylalcohol **9003-39-8**, Polyvinylpyrrolidone **19698-29-4**, Dipalmitoylphosphatidic acid **25322-68-3**, Polyethylene glycol **25322-69-4**, Polypropylene glycol **78543-25-6**, 1-Hexadecyl-2-palmitoylglycerophosphoethanolamine

97782-02-0
RL: ARG (Analytical reagent use); BUU (Biological use, unclassified); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(microspheres, gas filled; methods of computed tomog. using perfluorocarbon gaseous filled lipid microspheres as contrast agents)

RN 63-89-8 HCAPLUS
CN 3,5,9-Trioxa-4-phosphapentacosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[(1-oxohexadecyl)oxy]-, inner salt, 4-oxide, (7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 5681-36-7 HCAPLUS
CN Hexadecanoic acid, 1-[[[(2-aminoethoxy)hydroxyphosphinyl]oxy]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)



RN 7727-37-9 HCAPLUS
CN Nitrogen (8CI, 9CI) (CA INDEX NAME)

RN 9002-89-5 HCAPLUS
CN Ethenol, homopolymer (9CI) (CA INDEX NAME)

CM 1

CRN 557-75-5
CMF C2 H4 O



RN 9003-39-8 HCAPLUS
CN 2-Pyrrolidinone, 1-ethenyl-, homopolymer (9CI) (CA INDEX NAME)

CM 1

CRN 88-12-0
CMF C6 H9 N O



RN 19698-29-4 HCAPLUS
CN Hexadecanoic acid, 1-[(phosphonooxy)methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)



RN 25322-68-3 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-hydro-.omega.-hydroxy- (9CI) (CA INDEX NAME)



RN 25322-69-4 HCAPLUS
CN Poly[oxy(methyl-1,2-ethanediyl)], .alpha.-hydro-.omega.-hydroxy- (9CI) (CA INDEX NAME)



RN 78543-25-6 HCAPLUS
CN Hexadecanoic acid, 2-[[(2-aminoethoxy)hydroxyphosphinyl]oxy]-1-[(hexadecyloxy)methyl]ethyl ester (9CI) (CA INDEX NAME)



RN 97782-02-0 HCAPLUS
CN 9-Octadecenoic acid (9Z)-, 1-[[[[2-(2,5-dioxo-1-pyrrolidinyl)ethoxy]hydroxyphosphinyl]oxy]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RE.CNT 71
RE
(2) Anon; EP 0107559 1984 HCAPLUS
(3) Anon; EP 0077752 B1 1986 HCAPLUS
(4) Anon; EP 0231091 1987 HCAPLUS
(6) Anon; EP 0272091 1988 HCAPLUS
(10) Anon; EP 0361894 1990 HCAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT